Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline
Cutbacks And Threat Of Closure Hitting Small To Medium Biotechs
Don't cross over: this year has seen negative sentiment hitting biotech valuations, with very limited public market raises or IPOs. • Source: Alamy 
